Multiple metabolic parameters and visual assessment of 18F-FDG uptake heterogeneity of PET/CT in advanced gastric cancer and primary gastric lymphoma

Ren, Yixuan; Liu, Juan; Ling, Wang; Luo, Yuan; Ding, Xifeng; Shi, Aiqi; Liu, Jiangyan

doi:10.1007/s00261-020-02503-9

Cited by 7 publications

(12 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be used to detect specific manifestations of DILD after CHT, with clearly identifiable histologic patterns and appearance. This can aid our evaluation of treatment responses and provide guidance for subsequent treatment plans for patients [8] …”

Section: Discussionmentioning

confidence: 99%

“…This can aid our evaluation of treatment responses and provide guidance for subsequent treatment plans for patients. [8]…”

Section: Discussionmentioning

confidence: 99%

“…CT shows septal thickening and reticulation, multiple ground glass-like shadow or grid-shaped blur shadow, and lung consolidation, [6,7] which is common in lung periphery and under the pleura but cannot be used distinguish among DILD, pulmonary infection (PI), and lung infiltration. PET/CT can be used not only for diagnosis and staging but also to assess the treatment and related adverse by combining anatomical and functional images [8,9] . Few studies have evaluated DILD and PI in lymphoma patients using PET/CT [10] .…”

Section: Introductionmentioning

confidence: 99%

“…PET/CT can be used not only for diagnosis and staging but also to assess the treatment and related adverse by combining anatomical and functional images. [8,9] Few studies have evaluated DILD and PI in lymphoma patients using PET/CT. [10] In this study, we retrospectively reviewed lymphoma patients' clinical characteristics, laboratory examinations, and PET/CT imaging to investigate the prevalence of DILD and PI, evaluate the therapeutic effects, and guide future treatment.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

18F-FDG PET/CT imaging in the diagnosis of drug-induced lung disease and pulmonary infection in lymphoma

Lu¹,

Yang

2021

Medicine

View full text Add to dashboard Cite

Objective: Lymphoma is a hematological disease with high prevalence. Multi-cycle chemotherapy (CHT) or local radiotherapy is applied usually; however, adverse events have been reported, such as drug-induced lung disease (DILD). Positron emission tomography/computed tomography (PET/CT) is often used to evaluate the lesion, treatment effect, and prognosis of lymphoma. We investigated DILD and pulmonary infection (PI) after multi-cycle CHT in lymphoma patients, to identify DILD and PI, provide guidance for later treatment for them. Methods: In all, 677 patients diagnosed with lymphoma and who underwent CHT were included. These patients underwent 18 fluorodeoxyglucose ( 18 F-FDG) PET/CT before and after CHT at Shandong Cancer Hospital (affiliated with Shandong University) between April 2015 and November 2019. Fifty patients developed DILD, 41 patients had lung infections; lesion characteristics were analyzed based on clinical characteristics, laboratory examinations, and PET/CT imaging. Results: Among the 677 lymphoma patients, there were 50 cases of DILD, with an incidence rate of 7.4%. PET/CT showed an elevated 18 fluorodeoxyglucose uptake lung background, septal thickening and reticulation, multiple ground glass-like shadows, and grid-shaped blur shadows, which were more common in the lung periphery and under the pleura. The maximum standardized uptake value in the lung was 2.45 ± 0.52. Pulmonary infections occurred in 41 patients, and the maximum standardized uptake value was 4.05 ± 1.42. Age, sex, CHT cycle, Ann-Arbor stage, and lymphocyte levels were not significantly different between DILD and PI patients. Leukocyte and neutrophils showed significant differences; the PI patients had increased laboratory indexes of leukocyte and neutrophils. The mean number of CHT cycles was 4 cycles for DILD and PI. Conclusions: PET/CT imaging has high sensitivity and detection rates for primary and metastatic lymphoma lesions. DILD mostly occurs in the middle and late stages of CHT. Laboratory tests and PET/CT can evaluate the lesions and treatment effects, and provide guidance for subsequent treatment plans for patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…This can aid our evaluation of treatment responses and provide guidance for subsequent treatment plans for patients. [8]…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

18F-FDG PET/CT imaging in the diagnosis of drug-induced lung disease and pulmonary infection in lymphoma

Lu¹,

Yang

2021

Medicine

View full text Add to dashboard Cite

show abstract

“…However, 68 Ga-PSMA is mainly excreted through the kidney and bladder, affecting the observation of primary prostate lesions and pelvic metastases. Moreover, 68 Ga is not easily accessible, and the image quality is lower than 18 F. 18 F-FDG is the clinic's most commonly used imaging agent, and several studies have evaluated the value of 18 F-FDG PET/CT in diagnosis, staging, e cacy evaluation, and prognosis of PCa [9,10]. However, it has limitations in detecting prostate and pelvic lesions due to the slow proliferation, low glucose metabolic rate of PCa, and high accumulation of 18 F-FDG in the bladder after renal excretion.…”

Section: Introductionmentioning

confidence: 99%

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

Liu

Jiang

et al. 2023

Preprint

View full text Add to dashboard Cite

Purpose To explore the value of 18F-PSMA-1007 and 18F-FDG PET/CT in prostate cancer （PCa） patients, this study compared the performance of the two tracers to detect PCa and then analyzed the correlation between the metabolic parameters and serum PSA value. Finally, we evaluated the application of both tracers in the auxiliary staging of PCa patients. Methods Thirty patients diagnosed with PCa who underwent both 18F-PSMA-1007 and 18F-FDG PET/CT were enrolled. The detection rate, number, location of lesions, and metabolic parameters SUVs (SUVmax, SUVmean), PSMA-TV, MTV, TL-PSMA, TLG, and tumor-to-background ratio (TBR) were recorded and compared. The correlation between metabolic parameters and serum PSA was analyzed. Finally, the differences and consistency of both tracers for the same patient’s NM stage and clinical stage were compared. Results Patient analysis showed that 18F-PSMA-1007 PET/CT had a similar ability to identify the primary tumor and local recurrence (p=1.000) as 18F-FDG PET/CT but identified more patients with metastases (p=0.016), especially bone metastases (p=0.004). Lesion analysis showed that 18F-PSMA-1007 PET/CT identified more primary lesions, local recurrences, and metastases. It also had higher diagnostic efficacy for lymph nodes and bone metastases (both p<0.05). For lesions with positive uptake, the median SUVs and TBR of 18F-PSMA-1007 PET/CT were significantly higher than 18F-FDG PET/CT (all p<0.05). The median PSMA-TV was higher than the median MTV. Still, the difference was not statistically significant (p>0.05), while the median TL-PSMA was significantly higher than the median TLG (p<0.05). Volume-based metabolic parameters PSMA-TV, TL-PSMA, MTV, and TLG, were significantly and positively correlated with PSA (all p<0.05). In contrast, SUVs and TBR for the primary tumor or local recurrence were not associated with PSA. 18F-PSMA-1007 PET/CT identified more M1 patients and higher clinical stage, and it had higher diagnostic efficacy than 18F-FDG PET/CT (p<0.05). Conclusions 18F-PSMA-1007 PET/CT was a valuable imaging modality for PCa. It had better diagnostic efficacy, lesions detection, and a higher median value for metabolic parameters than 18F-FDG PET/CT. Volume-based metabolic parameters reflecting the total tumor burden were positively correlated with serum PSA levels. 18F-PSMA-1007 PET/CT had a higher clinical application value than 18F-FDG PET/CT for PCa patients.

show abstract

The role of baseline 2‐[¹⁸F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis

Albano,

Calabrò,

Dondi

et al. 2024

Hematological Oncology

View full text Add to dashboard Cite

Diffuse Large B‐Cell Lymphomas (DLCBL) and mucosa‐associated lymphoid tissue (MALT) are the two most common primary gastric lymphomas (PGLs), but have strongly different features. DLBCL is more aggressive, is frequently diagnosed at an advanced stage and has a poorer prognosis. The aim of this retrospective study was to explore the role of fluorine‐18‐fluorodeoxyglucose positron emission tomography/computed tomography (2‐[18F]‐FDG‐PET/CT) and radiomics features (RFs) in predicting the final diagnosis of patients with PGLs. Ninety‐one patients with newly diagnosed PGLs who underwent pre‐treatment 2‐[18F]‐FDG‐PET/CT were included. PET images were qualitatively and semi‐quantitatively analyzed by deriving maximum standardized uptake value body weight (SUVbw), maximum standardized uptake value lean body mass (SUVlbm), maximum standardized uptake value body surface area (SUVbsa), lesion to liver SUVmax ratio (L‐L SUV R), lesion to blood‐pool SUVmax ratio (L‐BP SUV R), metabolic tumor volume (gMTV) and total lesion glycolysis of gastric lesion (gTLG), total MTV (tMTV), TLG, and first‐order RFs (histogram‐related and shape related). Receiver‐operating characteristic (ROC) curve analyses were performed to determine the differential diagnostic values of PET parameters. The final diagnosis was DLBCL in 54 (59%) cases and MALT in 37 cases (41%). PGLs showed FDG avidity in 83 cases (90%), 54/54 of DLBCL and 29/37 of MALT. All PET/CT metabolic features, such as stage of disease and tumor size, were significantly higher in DLBCL than MALT; while the presence of H. Pylori infection was more common in MALT. At univariate analysis, all PET/CT metrics were significantly higher in DLBCL than MALT lymphomas, while among RFs only Shape volume_vx and Shape sphericity showed a significant difference between the two groups. In conclusion we demonstrated that 2‐[18F]‐FDG‐PET/CT parameters can potentially discriminate between DLBCL and MALT lymphomas with high accuracy. Among first‐order RFs, only Shape volume_vx and Shape sphericity helped in the differential diagnosis.

show abstract

Multiple metabolic parameters and visual assessment of 18F-FDG uptake heterogeneity of PET/CT in advanced gastric cancer and primary gastric lymphoma

Cited by 7 publications

References 34 publications

18F-FDG PET/CT imaging in the diagnosis of drug-induced lung disease and pulmonary infection in lymphoma

18F-FDG PET/CT imaging in the diagnosis of drug-induced lung disease and pulmonary infection in lymphoma

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

The role of baseline 2‐[¹⁸F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis

Contact Info

Product

Resources

About

Multiple metabolic parameters and visual assessment of 18F-FDG uptake heterogeneity of PET/CT in advanced gastric cancer and primary gastric lymphoma

Cited by 7 publications

References 34 publications

18F-FDG PET/CT imaging in the diagnosis of drug-induced lung disease and pulmonary infection in lymphoma

18F-FDG PET/CT imaging in the diagnosis of drug-induced lung disease and pulmonary infection in lymphoma

18 F-PSMA-1007 and 18 F-FDG PET/CT in patients with prostate cancer

The role of baseline 2‐[18F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis

Contact Info

Product

Resources

About

The role of baseline 2‐[¹⁸F]‐FDG‐PET/CT metrics and radiomics features in predicting primary gastric lymphoma diagnosis